Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
24/09/2026 12:26
BRIEF-United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application Sept 24 (Reuters) - United Laboratories International 3933.HK:
GROUP'S PRODUCT INSULIN DEGLUDEC AND LIRAGLUTIDE INJECTION MARKETING REGISTRATION APPLICATION BEEN ACCEPTED
APPLICATION ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million